FDG stands for fluorodeoxyglucose, a slightly modified form of glucose that has been tagged with a small amount of radioactive fluorine-18. Its full chemical name is 2-deoxy-2-[¹⁸F]fluoro-D-glucose. When injected into your bloodstream before a PET scan, FDG travels through your body just like regular sugar would, getting absorbed by cells that are hungry for energy. The radioactive tag then sends out signals that the PET scanner detects, producing a detailed map of metabolic activity throughout your tissues. That map is what makes FDG-PET one of the most widely used imaging tools in modern medicine, particularly for spotting and tracking cancer.
A Sugar Impostor Your Cells Cannot Finish Burning
To understand why FDG works, it helps to know the trick it plays on your cells. Normal glucose enters a cell through transporter proteins on the cell surface, then gets broken down step by step to produce energy. FDG enters the same way, through the same transporters, so the cell treats it like real sugar. But once inside, the cell hits a wall. After the first chemical step, FDG gets stuck. The cell’s machinery cannot process it any further because of a small structural change where a hydroxyl group has been swapped for a fluorine atom. So the partially processed FDG just accumulates inside the cell, unable to move forward or escape.
This “metabolic trapping” is the entire basis of PET imaging. Cells that consume a lot of glucose end up hoarding more FDG, and the radioactive fluorine-18 keeps emitting positrons that the scanner picks up. The result is a bright spot on the image wherever metabolic activity is high. Research has confirmed that FDG uptake in tumors tracks closely with the expression of glucose transporter proteins and hexokinase, the enzyme responsible for that first trapping step.1PubMed Central. 18F-FDG Uptake and PCNA, Glut-1, and Hexokinase-II Expressions in Cancers and Inflammatory Lesions of the Lung
Why Cancer Cells Light Up
Cancer cells are metabolic gluttons. Even when plenty of oxygen is available, many tumors preferentially burn glucose through a less efficient pathway, consuming far more sugar than normal tissue to fuel their rapid growth. This phenomenon was first described nearly a century ago and is still one of the core reasons FDG-PET scanning works so well for oncology.
At the molecular level, a transcription factor called HIF-1 drives much of this behavior. HIF-1 ramps up the production of glucose transporters and hexokinase, which are the two main gatekeepers controlling how much glucose a cell takes in and traps. Cancer-promoting gene mutations can push HIF-1 activity even higher. Animal studies have shown that knocking out a specific tumor-suppressor gene doubled glucose metabolism in tumor models, and clinical PET studies have found that roughly half to two-thirds of kidney cancers show FDG uptake, consistent with the expected frequency of that gene mutation in renal tumors.2PubMed Central. Warburg revisited: imaging tumour blood flow and metabolism
Not all cancers are equally FDG-hungry, though. Some slow-growing tumors, like certain well-differentiated thyroid cancers or low-grade prostate cancers, burn so little extra glucose that they barely register on a PET scan. On the other end, aggressive lymphomas and many lung cancers tend to light up intensely. This variability is not a flaw in the technology; it reflects the genuine metabolic differences between tumor types.
How Doctors Quantify What They See
When a radiologist reads your PET scan, they do not just eyeball the bright spots. They use a measurement called the standardized uptake value, or SUV. The SUV takes the amount of radioactive signal in a particular spot and adjusts it for how much FDG was injected and your body size. In theory, this removes patient-to-patient variability and gives a comparable number. An SUV of 1.0 means a region is taking up FDG at roughly the average rate you would expect if the tracer were spread evenly throughout the body. Cancerous tissue often produces SUVs well above that baseline, though the exact cutoff for “suspicious” depends on the organ and the clinical context.
In practice, SUV measurements carry some noise. Factors like how long you waited between injection and scanning, your blood sugar level at the time, and even the specific scanner model can all shift the numbers. A study of 200 patients found that liver and bone SUV readings gradually decreased as blood glucose climbed above about 160 mg/dL, which is why you are told to fast before the scan.3Iraqi Journal of Physics. Assessment of the Effect of Blood Glucose Levels on Standardized Uptake Value (SUV) and 18F-FDG Uptake at Tumors and Normal PET Examinations Despite these imperfections, SUV remains the standard metric for tracking how a tumor responds to treatment over time.4PubMed Central. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy
Where FDG Shows Up in a Healthy Body
If FDG traces glucose use, it will naturally appear in any organ that burns a lot of sugar under normal conditions. Your brain is the biggest consumer, accounting for a disproportionate share of total glucose metabolism. The heart muscle, liver, spleen, tonsils, and cerebellum all show consistent FDG uptake even in completely healthy people.5PubMed. Standardized uptake values of normal organs on 18F-fluorodeoxyglucose positron emission tomography and computed tomography imaging Your kidneys and bladder light up too, but for a different reason: they are the exit route. FDG that is not trapped in tissue gets filtered out through your urine, so the urinary system consistently glows on PET images.6Journal of Nuclear Medicine Technology. Prospective Evaluation of Physiologic Uptake Detected with True Whole-Body 18F-FDG PET/CT in Healthy Subjects
Radiologists learn to recognize these normal patterns so they do not mistake them for disease. A less well-known source of confusion is brown fat. Unlike regular white fat, brown fat burns calories to generate heat, and it can soak up FDG in the process. Brown fat deposits cluster in the neck, along the spine, and near major blood vessels in the chest. In some patients, especially younger and thinner individuals or those who were cold before the scan, brown fat can light up brightly enough to mimic abnormal lymph nodes.7Journal of Nuclear Medicine. Patterns of 18F-FDG Uptake in Adipose Tissue and Muscle: A Potential Source of False-Positives for PET Keeping the imaging suite warm and having patients avoid cold exposure beforehand helps minimize this artifact.
False Positives and What FDG Cannot Tell You
FDG is not a cancer-specific molecule. Any tissue burning a lot of glucose can light up, and that includes infections and inflammation. Bacterial infections, fungal infections, tuberculosis, sarcoidosis, and post-surgical healing have all produced intense FDG uptake that looked suspicious for cancer on PET scans.8PubMed Central. False positive and false negative FDG-PET scans in various thoracic diseases One review reported a false-positive rate of about 13% for PET/CT in the chest, largely driven by inflammatory cells at sites of infection or irritation.9CHEST. Endobronchial Foreign Body Mimicking Lung Malignancy on FDG-PET/CT Scan
The reason is straightforward: activated immune cells, particularly macrophages, are metabolically voracious. When your body mounts an inflammatory response, these cells ramp up glucose consumption in much the same way cancer cells do. This is a significant enough problem that researchers have explored whether anti-inflammatory medications like metformin could reduce inflammation-driven false positives in lung cancer imaging.10PubMed Central. Metformin as a strategy against false positives in (18)F-FDG PET/CT due to inflammation
False negatives happen too. Tumors that grow slowly, have low metabolic rates, or sit very close to organs that naturally light up (like the brain or bladder) can be missed. A small lesion near the kidney might get drowned out by the normal urinary FDG signal. This is why PET results are almost always interpreted alongside CT or MRI images, and why the clinical picture matters as much as what glows on the screen.
Why You Have to Fast Before the Scan
If you have ever been told to skip breakfast before a PET scan, the reason ties directly to how FDG works. FDG competes with regular glucose for entry into cells. If your bloodstream is flooded with sugar from a recent meal, your cells take up real glucose instead of FDG, and the scan becomes less sensitive. High insulin levels after eating also drive glucose into muscles and fat, spreading FDG around in ways that create a noisy background instead of clear contrast between normal and abnormal tissue.
Clinical guidelines recommend a minimum of six hours of complete fasting before injection. During that window, you should avoid anything containing sugar or carbohydrates, including gum, candy, and flavored water. Only plain water is permitted. Many centers also recommend eating a high-protein, low-carbohydrate diet for the 24 hours before the scan to further lower baseline glucose and insulin levels.11Journal of Nuclear Medicine Technology. 18F-FDG PET and PET/CT Patient Preparation: A Review of the Literature Diabetic patients need special attention, since their blood sugar can be harder to control. Most centers will check your glucose level before injecting FDG and may reschedule the scan if it is too high.
FDG-PET for the Brain
Cancer is the most common reason for an FDG-PET scan, but the brain was actually one of the first organs studied with this technology. Because the brain relies almost exclusively on glucose for energy, FDG-PET produces richly detailed maps of neural activity. In clinical practice, this is most useful for evaluating dementia.
Different types of dementia produce distinct patterns of reduced FDG uptake, giving neurologists a tool to distinguish between conditions that can look identical on standard MRI. In Alzheimer’s disease, the characteristic pattern involves decreased metabolic activity in certain association cortices and the posterior cingulate region, while the primary sensory and motor areas, the basal ganglia, and the cerebellum remain relatively active.12Journal of Nuclear Medicine. 18F-FDG PET Imaging in Neurodegenerative Dementing Disorders: Insights into Subtype Classification, Emerging Disease Categories, and Mixed Dementia with Copathologies Frontotemporal dementia, by contrast, hits the frontal and temporal lobes hardest. These metabolic fingerprints can help clinicians make the right diagnosis when symptoms overlap, which matters because the diseases progress differently and may respond to different treatments.
FDG-PET also plays a role in epilepsy evaluation. Between seizures, the part of the brain responsible for generating them often shows reduced glucose metabolism. Identifying that zone on PET can help surgeons plan where to operate in patients whose seizures are not controlled by medication.
Scanning the Heart for Inflammation
Using FDG-PET to image the heart requires a clever workaround. The heart is a muscle, and like any muscle, it happily burns glucose under normal conditions. That means a standard FDG-PET scan would show the entire heart lighting up, making it impossible to spot abnormal patches of inflammation. The solution is to shift the heart’s fuel source away from glucose before the scan.
Patients undergoing cardiac FDG-PET, most commonly to evaluate a condition called cardiac sarcoidosis, are placed on a ketogenic diet or a prolonged fast to push the heart into burning fats instead of sugar. When the preparation works, the normal heart muscle goes dark on the scan, and any areas of active inflammation that are still consuming glucose stand out clearly. FDG-PET with this approach is considered the standard imaging method for detecting myocardial inflammation in cardiac sarcoidosis.13PubMed. Relationship of Ketosis With Myocardial Glucose Uptake Among Patients Undergoing FDG PET/CT for Evaluation of Cardiac Sarcoidosis
Getting the preparation right matters. Research comparing different dietary protocols found that a more intensive 72-hour daytime ketogenic diet with three nights of fasting produced much better suppression of normal heart glucose uptake than shorter protocols. In that study, unwanted background heart activity appeared in only about 6% of patients using the intensive protocol, compared with roughly 38% on a 24-hour ketogenic diet and 59% on an 18-hour fast alone.14PubMed. The active papillary muscle sign in 18F-FDG PET/CT cardiac sarcoidosis exams and its relationship with myocardial suppression Interestingly, once a patient reaches adequate ketosis, pushing ketone levels even higher does not seem to help further, suggesting there is a threshold rather than a dose-dependent effect.15European Heart Journal – Imaging Methods and Practice. Magnitude of Serum β-Hydroxybutyrate Elevations and Myocardial Glucose Suppression in 18F-FDG PET-CT for Cardiac Sarcoidosis
Tracking Mysterious Fevers and Blood Vessel Inflammation
When a patient has a persistent unexplained fever and the usual workup comes up empty, FDG-PET can sometimes find the answer. Because inflammation anywhere in the body drives up local glucose metabolism, a whole-body PET scan can reveal hidden infections, abscesses, or inflammatory conditions that other imaging misses. One particularly valuable application is detecting large-vessel vasculitis, a condition where the immune system attacks the walls of major arteries like the aorta. These inflamed vessel walls light up on FDG-PET, showing which arteries are affected and how active the disease is.16PubMed. Large vessel vasculitis as cause of fever of unknown origin (FUO) or systemic inflammation
This use case highlights something important about FDG: its lack of specificity for cancer, which is a limitation in oncology, becomes a strength elsewhere. The same metabolic signal that causes false positives in cancer screening becomes the diagnostic signal itself when you are hunting for hidden inflammation.
Monitoring Whether Treatment Is Working
Traditionally, doctors tracked cancer treatment by measuring whether tumors physically shrank on CT scans, using a system called RECIST. But metabolic changes often happen before size changes. A tumor might stop consuming glucose weeks before it visibly shrinks, and a mass that stays the same size on CT might already be metabolically dead tissue. FDG-PET allows oncologists to catch those early metabolic shifts.
A newer set of criteria called PERCIST uses FDG-PET uptake changes to judge treatment response. When researchers pooled data comparing RECIST and PERCIST evaluations in patients with solid tumors, the two systems disagreed in about 38% of cases. The overall response rate was significantly higher when judged by metabolic criteria rather than size alone. In most of the discordant cases, PERCIST upgraded the response, meaning PET detected improvement that CT missed.17PubMed Central. Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review This can spare patients from unnecessary treatment switches when their current therapy is actually working.
Radiation Exposure From an FDG-PET Scan
FDG contains radioactive fluorine-18, so a PET scan does expose you to ionizing radiation. The total dose comes from two sources: the injected FDG itself, and the CT scan that is almost always performed alongside PET for anatomical reference. Estimates from different centers vary somewhat depending on the injected dose and the CT protocol used.
One large real-world analysis at a high-volume center found a mean total effective dose of roughly 10 millisieverts (mSv) for a torso PET/CT scan, with the PET portion contributing about two-thirds and the CT the rest.18Journal of Nuclear Medicine. Effective Dose Estimation of Torso 18F FDG PET/CT Imaging from Real-World Data in a High-Volume Center Another study using a higher FDG dose and a full diagnostic CT estimated total doses closer to 14 to 17 mSv.19PubMed Central. Estimation of radiation dose to patients from (18) FDG whole body PET/CT investigations using dynamic PET scan protocol A study of lymphoma patients receiving serial scans found a mean dose of about 12 mSv per scan, with the CT component accounting for roughly three-quarters of the total.20PubMed. Effective dose and risk assessment in 18F-FDG PET/CT examinations of lymphoma patients using updated dose coefficients
For context, the average American receives about 3 mSv per year from natural background radiation, so a PET/CT scan is a meaningful but not extraordinary addition. The dose is comparable to a few years of background exposure compressed into one session. In cancer patients, where the scan can directly change treatment decisions, the clinical benefit overwhelmingly outweighs the small incremental radiation risk. For patients who need repeated scans over time, particularly lymphoma patients who may undergo several rounds of monitoring, cumulative dose becomes something physicians keep an eye on.
FDG-PET in Children
Children are more sensitive to radiation than adults, and they have more years of life ahead in which any radiation-related risk could theoretically manifest. For this reason, pediatric PET protocols use less FDG. The standard approach bases the injected dose on the child’s weight, typically around 5.3 MBq per kilogram of body weight, with a minimum dose to maintain image quality.21Journal of Nuclear Medicine. Weight-Based, Low-Dose Pediatric Whole-Body PET/CT Protocols Newer research has pushed to reduce pediatric doses even further, with one study developing a dedicated dosing formula that allows considerably lower administered activity compared with existing pediatric guidelines while still producing diagnostic-quality images.22PubMed Central. A dedicated paediatric [18F]FDG PET/CT dosage regimen
Pediatric PET also poses practical challenges. Young children may not be able to hold still for the 20 to 30 minutes the scan takes, so sedation or general anesthesia is sometimes required. Fasting instructions need to be age-appropriate and carefully communicated to parents. Despite these hurdles, FDG-PET plays a key role in pediatric oncology, especially for staging and monitoring lymphoma and certain solid tumors.
The Clock Problem With Fluorine-18
Fluorine-18 has a half-life of about 110 minutes, meaning that half of its radioactivity disappears roughly every two hours.23PubMed Central. Fluorine-18 radiochemistry, labeling strategies and synthetic routes This is actually an elegant compromise: long enough to synthesize the tracer, ship it to a hospital, inject it, wait for it to distribute through the body, and complete the scan, but short enough that the radiation clears quickly once the scan is done. By the end of the day, most of the radioactivity has decayed away.
The short half-life does create logistical pressure. FDG is produced in a cyclotron, a particle accelerator that bombards enriched water with protons to create fluorine-18, which is then chemically attached to a glucose molecule. Because the product starts decaying immediately, it has to be manufactured the same morning it will be used and rushed to the imaging center. Most hospitals do not have their own cyclotrons, so they depend on regional radiopharmacies that produce FDG in batches and deliver it on tight schedules. A broken-down delivery vehicle or a cyclotron malfunction can cancel an entire morning of patient scans. This supply-chain fragility is one of the underappreciated constraints of PET imaging, and it is part of why PET scans cost more and require more advance planning than a standard CT or MRI.